DOCOSANOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOCOSANOL (DOCOSANOL).
Docosanol is a saturated fatty alcohol that inhibits fusion between the host cell plasma membrane and the herpes simplex virus envelope, thereby preventing viral entry and replication.
| Metabolism | Docosanol is metabolized via beta-oxidation to long-chain fatty acids; no significant cytochrome P450 metabolism. |
| Excretion | Docosanol is a topical agent with negligible systemic absorption; no significant renal or fecal elimination occurs after topical application. In animal studies, less than 1% of a topical dose was excreted in urine or feces as unchanged drug or metabolites. |
| Half-life | Due to negligible systemic absorption, a terminal elimination half-life is not defined for topical docosanol. In vitro studies of hepatic metabolism suggest a plasma half-life of approximately 1 hour if systemically absorbed, but clinical relevance is absent. |
| Protein binding | Docosanol is not significantly protein-bound due to minimal systemic absorption; in vitro data indicate binding to albumin and lipoproteins at <10%. |
| Volume of Distribution | Not applicable for topical use; if systemically absorbed (hypothetically), Vd would be expected to be >10 L/kg due to high lipophilicity, but no human data exist. |
| Bioavailability | Topical: Bioavailability is negligible (<1%) as docosanol acts locally on the skin and is not designed for systemic delivery. Oral bioavailability is not studied; the drug is not administered orally. |
| Onset of Action | Topical application: Healing of herpes simplex lesions typically begins within 1-2 days of initiating therapy, with full resolution in 4-6 days. Reduction in symptoms (itching, pain) may occur within hours. |
| Duration of Action | Topical: Application every 2-3 hours while awake for 5-10 days; the duration of action per dose is approximately 2-3 hours, corresponding to the dosing interval. Clinical benefit requires repeated application during prodrome and active lesion phase. |
| Molecular Weight | 326.56 |
Apply a thin layer of 10% cream to affected area 5 times daily until healing is complete, typically 4-6 days.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required. |
| Liver impairment | No dosage adjustment required. |
| Pediatric use | For children aged 12 years and older, same as adult dosing. Safety and efficacy in children under 12 years not established. |
| Geriatric use | No specific dosage adjustment recommended; use same dosing as for younger adults. |
| 1st trimester | Limited data; topical application unlikely to cause significant systemic exposure. No known teratogenic risk. |
| 2nd trimester | Topical use considered safe; minimal systemic absorption. |
| 3rd trimester | Topical use considered safe; minimal systemic absorption. |
Clinical note
Comprehensive clinical and safety monograph for DOCOSANOL (DOCOSANOL).
| Placental transfer | No studies available; due to minimal systemic absorption after topical application, placental transfer is likely negligible. |
| Breastfeeding | Topical application of docosanol results in negligible systemic absorption, and it is unlikely to be excreted into breast milk. Use is considered compatible with breastfeeding. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to docosanol or any component of the formulation
| Precautions | Avoid application to mucous membranes (e.g., eyes, mouth, nose)., Do not use in immunocompromised patients without physician approval., Discontinue if irritation or allergic reaction occurs. |
| Food/Dietary | No clinically significant food interactions. |
| Clinical Pearls | Docosanol is a topical antiviral indicated for recurrent herpes simplex labialis. Apply at first prodromal symptoms; efficacy correlates with early initiation. No systemic absorption; safe in immunocompromised. Not for genital herpes or mucosal use. |
Loading safety data…
| L1 - Safe |
| Teratogenic Risk | No evidence of teratogenicity in animal studies; insufficient human data. Clinical use not associated with major malformations; risk cannot be excluded. First trimester: no documented fetal risk. Second and third trimesters: no adverse fetal effects reported. |
| Fetal Monitoring | No specific fetal monitoring required. Observe for local skin reactions at application site. |
| Fertility Effects | No known effects on fertility in animal studies; no human data. |
| Patient Advice | Apply cream at the first sign of a cold sore (tingling, itching, redness). · Wash hands before and after application to avoid spreading the virus. · Use five times daily until the sore heals, usually within 10 days. · Avoid sharing the tube with others. · Stop use and consult a doctor if sore worsens or persists beyond 10 days. · Do not apply inside the mouth or on other mucous membranes. |